Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,654,254
  • Shares Outstanding, K 39,387
  • Annual Sales, $ 53,020 K
  • Annual Income, $ -36,560 K
  • 60-Month Beta 1.54
  • Price/Sales 31.84
  • Price/Cash Flow N/A
  • Price/Book 5.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.84
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -1.14
  • Prior Year 0.29
  • Growth Rate Est. (year over year) -389.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.94 +20.21%
on 11/14/19
45.58 -7.85%
on 11/25/19
+6.81 (+19.35%)
since 11/13/19
3-Month
23.76 +76.77%
on 09/30/19
45.58 -7.85%
on 11/25/19
+16.38 (+63.93%)
since 09/13/19
52-Week
10.72 +291.79%
on 12/24/18
45.58 -7.85%
on 11/25/19
+27.07 (+181.31%)
since 12/13/18

Most Recent Stories

More News
Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patients...

BGNE : 176.03 (-1.75%)
ZYME : 42.00 (-2.01%)
Zymeworks Announces Selection of ZW25 Abstract for Mini Oral Presentation at the European Society for Medical Oncology Asia (ESMO Asia) Congress

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the selection of an abstract highlighting updated single agent data from...

ZYME : 42.00 (-2.01%)
Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -1.45% and 1.22%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ZYME : 42.00 (-2.01%)
Zymeworks Files Automatic Shelf Registration Statement and Enters into At-The-Market Equity Offering Sales Agreement

Zymeworks Inc. (NYSE: ZYME), a clinical'stage biopharmaceutical company developing multifunctional therapeutics, announced today that it has filed an automatic shelf registration statement on Form S-3...

ZYME : 42.00 (-2.01%)
Zymeworks Reports 2019 Third Quarter Financial Results

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2019.

ZYME : 42.00 (-2.01%)
Zymeworks to Present at Stifel 2019 Healthcare Conference

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present at the upcoming Stifel 2019 Healthcare Conference...

ZYME : 42.00 (-2.01%)
Zymeworks Announces Phase 1 Data for ZW25 in Combination with Chemotherapy in Advanced Gastroesophageal Adenocarcinoma at AACR-NCI-EORTC International Conference

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announces the first data from its Phase 1 study evaluating novel bispecific antibody...

ZYME : 42.00 (-2.01%)
Zymeworks Appoints Chief People Officer

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the appointment of Kathryn O'Driscoll to the executive team as Chief People...

ZYME : 42.00 (-2.01%)
Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at European Society for Medical Oncology (ESMO) Congress

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated data from the ongoing multi-center Phase 1 clinical trial evaluating...

ZYME : 42.00 (-2.01%)
Zymeworks Announces New Chair of Board of Directors and Voluntary Delisting from the TSX

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Lota Zoth has been appointed as its Chair of the Board of Directors....

ZYME : 42.00 (-2.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ZYME with:

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 44.21
1st Resistance Point 43.10
Last Price 42.00
1st Support Level 41.29
2nd Support Level 40.59

See More

52-Week High 45.58
Last Price 42.00
Fibonacci 61.8% 32.26
Fibonacci 50% 28.15
Fibonacci 38.2% 24.04
52-Week Low 10.72

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar